How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypogonadal-osteoporosis-in-males.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypogonadal Osteoporosis in Males — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypogonadal Osteoporosis in Males (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypogonadal Osteoporosis in Males, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Infuvite Adult	Colecalciferol	Novartis	Vitamin D	Vitamin D3 receptor	2000-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
alendronate	alendronate	Massachusetts General Hospital		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Calciferol	Calciferol	Department of Medical Services Ministry of Public Health of Thailand		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis · 2 drugs in Hypogonadal Osteoporosis in Males
Children's Hospital Medical Center, Cincinnati · 1 drug in Hypogonadal Osteoporosis in Males
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Hypogonadal Osteoporosis in Males
Esjay Pharma · 1 drug in Hypogonadal Osteoporosis in Males
Massachusetts General Hospital · 1 drug in Hypogonadal Osteoporosis in Males
Merck And Co Inc · 1 drug in Hypogonadal Osteoporosis in Males
· 1 drug in Hypogonadal Osteoporosis in Males
University of Arkansas · 1 drug in Hypogonadal Osteoporosis in Males

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypogonadal Osteoporosis in Males:

Cite this brief

Drug Landscape (2026). Hypogonadal Osteoporosis in Males — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypogonadal-osteoporosis-in-males. Accessed 2026-06-10.

Hypogonadal Osteoporosis in Males full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing